The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

Fintel reports that on May 28, 2025, Scotiabank initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a ...

Arcturus And The Struggle For Substantive Justice. Legal News and Analysis - India - Intellectual Property - Conventus Law ...

Detailed price information for Vigil Neuroscience Inc (VIGL-Q) from The Globe and Mail including charting and trades.

The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

During the last three months, 7 analysts shared their evaluations of Arcturus Therapeutics (NASDAQ:ARCT), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...

Based on the current pipeline and programs, the cash runway is expected to extend into 2028 with the re-allocation of resources to the therapeutics programs. The Arcturus logo and other trademarks ...

Arcturus Therapeutics Holdings Inc. (ARCT) reported its first-quarter 2025 financial results, revealing a significant revenue shortfall and a net loss that missed analyst expectations. Despite the ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and ...